接受辅助化疗的III期胃癌患者复发后生存:JACCRO GC-07研究的事后分析
基于III期JACCRO GC-07试验的事后分析,比较接受多西他赛联合S-1(DS)或S-1单药辅助化疗的III期胃癌患者复发后生存(PRS)。DS组161例和S-1组216例复发,中位PRS分别为12.6个月和11.4个月(HR 0.98,95%CI 0.79-1.22;p=0.84)。复发后接受化疗者中位PRS分别为14.5个月和13.7个月(HR 1.04,95%CI 0.81-1.34;p=0.76)。
要点
- DS组与S-1组复发后中位PRS分别为12.6个月和11.4个月,无显著差异(HR 0.98,p=0.84)。
- 复发后接受化疗者中位PRS分别为14.5个月和13.7个月,无显著差异(HR 1.04,p=0.76)。
- 无论辅助化疗方案或复发时间,含铂化疗较非含铂化疗PRS更长。
核心结论
- 接受DS或S-1单药辅助化疗的患者复发后生存相似。
- 复发后接受化疗的两组患者PRS也相似。
- 含铂化疗可能是完成辅助DS后复发患者的最佳治疗,无论复发时间。
研究设计与样本
- JACCRO GC-07研究的事后分析,比较辅助化疗组间及复发后化疗方案间的复发后生存(PRS)。
- DS组441例中161例复发,S-1组452例中216例复发。
- 术后随访5年。
主要发现
- DS组与S-1组复发后中位PRS分别为12.6个月和11.4个月(HR 0.98,95%CI 0.79-1.22;p=0.84)。
- 复发后接受化疗者中,DS组115例与S-1组165例的中位PRS分别为14.5个月和13.7个月(HR 1.04,95%CI 0.81-1.34;p=0.76)。
- 含铂化疗较非含铂化疗PRS更长,无论辅助化疗方案或复发时间。
临床怎么用
- 作者认为,含铂化疗可能是完成辅助DS后复发患者的最佳治疗,无论复发时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As adjuvant chemotherapy for stage III gastric cancer, the phase III (JACCRO GC-07) trial showed that docetaxel plus S-1 (DS) was superior to S-1 in terms of recurrence-free and overall survival. However, whether adding docetaxel to S-1 in the adjuvant setting affects survival after recurrence remains unclear. The optimal treatment strategy for patients who develop recurrence during or after DS has also been controversial. METHODS: We used results from JACCRO GC-07 to investigate post-recurrence survival (PRS) in patients who developed recurrence during or after completing adjuvant chemotherapy. PRS was compared between adjuvant groups and among post-recurrence chemotherapeutic regimens. RESULTS: During 5 years of follow-up after surgery, 161 of 441 patients in the DS group and 216 of 452 patients in the S-1 group developed recurrence, with median PRS of 12.6 and 11.4 months, respectively (hazard ratio [HR] 0.98, 95 % confidence interval [CI] 0.79-1.22; p = 0.84). Among patients with recurrence, 115 patients in the DS group and 165 patients in the S-1 group received chemotherapy, and median PRS was 14.5 and 13.7 months, respectively (HR 1.04, 95 %CI 0.81-1.34; p = 0.76). Platinum-based chemotherapy resulted in longer PRS than non-platinum chemotherapy, regardless of the adjuvant chemotherapeutic regimen or time of recurrence. CONCLUSIONS: PRS was similar between patients who received adjuvant chemotherapy with DS or with S-1 alone. PRS was also similar between groups of patients who received chemotherapy after recurrence. Platinum-based chemotherapy might be the optimal treatment for patients who develop recurrence after completing adjuvant DS, regardless of the time of recurrence.
引用
- Ishida H, Sunakawa Y, Kodera Y, et al. Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study. Eur J Cancer. 2025. PMID: 39999670. doi:10.1016/j.ejca.2025.115322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。